Preoperative predictors that impact the survival and outcome of patients undergoing secondary cytoreduction for ovarian cancer

References

• American Cancer Society. 2014. Cancer facts and figures 2014. Atlanta: American Cancer Society.
   Google Scholar
• Ayhan A, Gultekin M, Taskiran C, Aksan G, Celik NY, Dursun P, et al. 2006. The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience. American Journal of Obstetrics and Gynecology 194:49–56.
   PubMed Web of Science ®Google Scholar
• Berek J, Hacker N, Lagasse L. 1983. Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstetrics and Gynecology 61:189–193.
   PubMed Web of Science ®Google Scholar
• Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. 2002. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. Journal of Clinical Oncology 20:1248–1259.
   PubMed Web of Science ®Google Scholar
• Cormio G, Di Vagno G, Cazzolla A, Bettocchi S, Di Gesu G, Loverro G, et al. 1999. Surgical treatment of recurrent ovarian cancer: report of 21 cases and a review of the literature. European Journal of Obstetrics and Gynecology Reproductive Biology 86:185–188.
   PubMed Web of Science ®Google Scholar
• Du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, et al. 2003. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of National Cancer Institute 95:1320–1329.
   PubMed Web of Science ®Google Scholar
• Eisenkop SM, Friedman RL, Spirtos NM. 2000. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 88:144–153.
   PubMed Web of Science ®Google Scholar
• Frederick PJ, Ramirez PT, Mcquinn L, Milam MR, Weber DM, Coleman RL, et al. 2011. Preoperative factors predicting survival after secondary cytoreduction for recurrent ovarian cancer. International Journal of Gynecologic Cancer 21:831–836.
   PubMed Web of Science ®Google Scholar
• Gadducci A, Iacconi P, Cosio S, Fanucchi A, Cristofani R, Riccardo Genazzani A. 2000. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecologic Oncology 79:344–349.
   PubMed Web of Science ®Google Scholar
• Harlan LC, Clegg LX, Trimble EL. 2003. Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. Journal of Clinical Oncology 21:3488–3494.
   PubMed Web of Science ®Google Scholar
• Harter P, Du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, et al. 2006. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Annals of Surgical Oncology 13:1702–1710.
   PubMed Web of Science ®Google Scholar
• Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, et al. 2011. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. International Journal of Gynecologic Cancer 21:289–295.
   PubMed Web of Science ®Google Scholar
• Janicke F, Holscher M, Kuhn W, Von Hugo R, Pache L, Siewert JR, et al. 1992. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer 70:2129–2136.
   PubMed Web of Science ®Google Scholar
• Lorusso D, Mancini M, Di Rocco R, Fontanelli R, Raspagliesi F. 2012. The role of secondary surgery in recurrent ovarian cancer. International Journal of Surgical Oncology 2012:613980.
   PubMedGoogle Scholar
• Mahdi H, Maurer KA, Nutter B, Rose PG. 2015. The impact of percent reduction in CA-125 levels on prediction of the extent of interval cytoreduction and outcome in patients with advanced-stage cancer of müllerian origin treated with neoadjuvant chemotherapy. International Journal of Gynecologic Cancer 25:823–829.
   PubMed Web of Science ®Google Scholar
• Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, et al. 1991. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. Journal of Clinical Oncology 9:389–393.
   PubMed Web of Science ®Google Scholar
• Medina-Franco H, García-Alvarez MN, Ortiz-López LJ, Cuairán JZ. 2008. Predictors of adverse surgical outcome in the management of malignant bowel obstruction. Revista de Investigacion Clinica. Clinical and Translational Investigation 60:212–216.
   Web of Science ®Google Scholar
• Morris M, Gershenson DM, Wharton JT. 1989. Secondary cytoreductive surgery in epithelial ovarian cancer: nonresponders to first-line therapy. Gynecologic Oncology 33:1–5.
   PubMed Web of Science ®Google Scholar
• Onda T, Yoshikawa H, Yasugi T, Yamada M, Matsumoto K, Taketani Y. 2005. Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection. British Journal of Cancer 92:1026–1032.
   PubMed Web of Science ®Google Scholar
• Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. 2003. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. Journal of Clinical Oncology 21:3194–3200.
   PubMed Web of Science ®Google Scholar
• Pecorelli S, Sartori E, Santin A. 1994. Follow-up after primary therapy: management of the symptomatic patient-surgery. Gynecologic Oncology 55:S138–S142.
   PubMed Web of Science ®Google Scholar
• Pfisterer J, Harter P, Canzler U, Richter B, Jackisch C, Hahmann M, et al. 2005. The role of surgery in recurrent ovarian cancer. International Journal of Gynecological Cancer 15 Suppl 3:195–198.
   PubMedGoogle Scholar
• Segna RA, Dottino PR, Mandeli JP, Konsker K, Cohen CJ. 1993. Secondary cytoreduction for ovarian cancer following cisplatin therapy. Journal of Clinical Oncology 11:434–439.
   PubMed Web of Science ®Google Scholar
• Tay EH, Grant PT, Gebski V, Hacker NF. 2002. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstetrics and Gynecology 99:1008–1013.
   PubMed Web of Science ®Google Scholar
• Tian WJ, Chi DS, Sehouli J, Trope CG, Jiang R, Ayhan A, et al. 2012. A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Annals of Surgical Oncology 19:597–604.
   PubMed Web of Science ®Google Scholar
• Vaccarello L, Rubin SC, Vlamis V, Wong G, Jones WB, Lewis JL, et al. 1995. Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response. Gynecologic Oncology 57:61–65.
   PubMed Web of Science ®Google Scholar
• Whitney C, Spirtos N. 2009. Gynecologic oncology group surgical procedures manual. Philadelphia: Gynecologic Oncology Group.
   Google Scholar
• Winter WE, 3rd, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose P. 2007. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology 25:3621–3367.
   PubMed Web of Science ®Google Scholar
• Zang RY, Li ZT, Tang J, Cheng X, Cai SM, Zhang ZY, et al. 2004. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer 100:1152–1161.
   PubMed Web of Science ®Google Scholar